Windtree Therapeutics (WINT) News Today $0.21 -0.01 (-4.02%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period WINT stock touches 52-week low at $0.21 amid sharp annual declineJanuary 21 at 10:11 PM | msn.comWindtree Therapeutics Appoints Leanne Kelly to Board of Directors and Audit CommitteeJanuary 21 at 2:05 AM | americanbankingnews.comWindtree Therapeutics Secures Patent in Japan for Cancer Treatment PlatformJanuary 19 at 10:44 PM | msn.comWindtree Therapeutics Appoints Leanne Kelly to Board, Advances New Growth StrategyJanuary 17, 2025 | msn.comWindtree announces issuance of patent in Japan for oncology pipelineJanuary 16, 2025 | markets.businessinsider.comWarrington’s Windtree Therapeutics Eyes Acquisitions to Stay AfloatJanuary 15, 2025 | msn.comWindtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology PipelineJanuary 15, 2025 | markets.businessinsider.comWindtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology PipelineJanuary 15, 2025 | globenewswire.comWindtree Announces the Addition of Leanne Kelly to Its Board of DirectorsJanuary 13, 2025 | globenewswire.comWindtree Therapeutics Highlights Istaroxime’s Promise for Cardiogenic ShockDecember 19, 2024 | msn.comWindtree Therapeutics announces presentation highlighting istaroximeDecember 17, 2024 | markets.businessinsider.comWindtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials ConferenceDecember 16, 2024 | finance.yahoo.comWindtree Therapeutics announces new istaroxime patent filingDecember 11, 2024 | markets.businessinsider.comWindtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial ArrhythmiaDecember 9, 2024 | globenewswire.comH.C. Wainwright Sticks to Their Hold Rating for Windtree Therapeutics (WINT)December 5, 2024 | markets.businessinsider.comWindtree Therapeutics announces partnership with New Growth AdvisorsDecember 5, 2024 | markets.businessinsider.comWindtree Therapeutics Engages New Growth Advisors to Explore Strategic OpportunitiesDecember 5, 2024 | msn.comWindtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic TransactionDecember 4, 2024 | globenewswire.comWindtree Therapeutics Reports Q3 Results and Highlights Key Business AchievementsDecember 1, 2024 | msn.comWindtree Therapeutics Reports Q3 2024 Financial ResultsNovember 28, 2024 | markets.businessinsider.comWindtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business UpdatesNovember 28, 2024 | markets.businessinsider.comWindtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business UpdatesNovember 27, 2024 | globenewswire.comLeadership Transition at Windtree Therapeutics: Fraser Retires, Latkin Takes HelmNovember 16, 2024 | msn.comWindtree Announces Leadership Transition Plan With Industry VeteransNovember 14, 2024 | markets.businessinsider.comWINT: Patient Enrollment in SEISMiC C Trial Starts, Patent Position ExpandsNovember 13, 2024 | finance.yahoo.comWindtree Therapeutics Secures Hong Kong Patent for Istaroxime in Heart Failure TreatmentNovember 6, 2024 | msn.comWindtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong KongNovember 5, 2024 | finance.yahoo.comWindtree Therapeutics Begins SEISMiC C Trial for Advanced Cardiogenic ShockNovember 1, 2024 | msn.comWindtree Therapeutics Secures Global Patent Filings for IstaroximeOctober 25, 2024 | msn.comWindtree Therapeutics completes national phase filings for istaroximeOctober 24, 2024 | finance.yahoo.comWindtree Therapeutics Prepares to Highlight Istaroxime Progress at ThinkEquity ConferenceOctober 23, 2024 | msn.comWindtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the WorldOctober 23, 2024 | globenewswire.comWindtree To Present at the ThinkEquity Conference on October 30thOctober 21, 2024 | markets.businessinsider.comWindtree Therapeutics Secures Patent for Heart Failure Treatment in JapanOctober 18, 2024 | msn.comWindtree Announces Expansion of Patents with Issuance of Istaroxime Patent for JapanOctober 17, 2024 | globenewswire.comWINT: Lead Drug Candidates, Multiple Programs, Several Upcoming Expected MilestonesOctober 14, 2024 | msn.comWindtree Announces Publication of Positive Istaroxime Phase 2b Study Trial DesignOctober 10, 2024 | finance.yahoo.comWindtree Therapeutics Publishes SEISMiC Phase 2b Trial Design for Cardiac TreatmentOctober 10, 2024 | msn.comWindtree Therapeutics Announces Recent Stock TransactionsOctober 6, 2024 | uk.investing.comWindtree reports positive heart failure drug study resultsOctober 2, 2024 | uk.investing.comWindtree Therapeutics Announces Positive Results in Heart Failure StudyOctober 2, 2024 | msn.comWindtree Therapeutics Reports Posive Topline Data From Phase 2b SEISMiC Extension StudySeptember 30, 2024 | markets.businessinsider.comWindtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic ShockSeptember 30, 2024 | globenewswire.comWindtree Therapeutics Announces Key Investor Day for Groundbreaking Heart TreatmentSeptember 28, 2024 | msn.comWindtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ETSeptember 26, 2024 | globenewswire.comWindtree stock slides amid Phase 2b data for istaroxime for cardiogenic shockSeptember 26, 2024 | msn.comWindtree Therapeutics Announces Promising Results for Heart Failure DrugSeptember 26, 2024 | msn.comWindtree Therapeutics: Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic ShockSeptember 26, 2024 | finanznachrichten.deWindtree Announce Positive Results From Phase 2b Study Of Istaroxime In Early Cardiogenic ShockSeptember 26, 2024 | markets.businessinsider.comWindtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic ShockSeptember 25, 2024 | globenewswire.com Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Email Address WINT Media Mentions By Week WINT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. WINT News Sentiment▼0.090.63▲Average Medical News Sentiment WINT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. WINT Articles This Week▼71▲WINT Articles Average Week Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MYNZ News Today INDP News Today AIMD News Today BFRI News Today ADXN News Today EGRX News Today AWH News Today BLRX News Today CYCN News Today CDT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:WINT) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free WINT Stock Alerts